Main menu

Uncovering global genetic diversity for equitable precision medicine


In this webinar, Francisco de la Vega (CTO, Galatea Bio) discusses the underrepresentation of global genetic diversity in current resources, especially for non-European and admixed populations, and how this hampers the discovery of new therapeutic targets.​

He shares two studies – first on familial hypercholesterolemia in an admixed cohort, which uncovered novel genetic contributors to the disease and confirmed them with Oxford Nanopore long-read sequencing.

In the second, nanopore sequencing was used on a cohort of understudied African diaspora populations in the Americas (CAAPA), showing how this data can enrich variant catalogues, support clinical interpretation, and help drive more equitable precision medicine.

Please note:

This is independent, investigator-led research using Oxford Nanopore technology. Oxford Nanopore products are for research use only, and not for use in diagnostic procedures.

Authors: Francisco de la Vega (CTO at Galatea Bio), Cora Vacher (Market Segment Associate Director for Human Genetics, Oxford Nanopore Technologies)

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

联系我们

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

关于 Oxford Nanopore

Contact us 领导团队 媒体资源和联系方式 投资者 在 Oxford Nanopore 工作 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag